COVID

Immune-suppressing drug does not improve COVID-19 recovery: study

Previous studies suggested that fostamatinib may suppress inflammatory responses triggered by COVID-19 and mitigate ongoing lung injury, decreasing mortality and oxygen requirements.

Supercomputing redesign of a COVID monoclonal antibody

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.

A team approach to care 

LSU baseball fan sporting a new set of lungs after VUMC transplant

CDC encourages additional COVID-19 vaccine dose for patients 65 and older

CDC changes community COVID-19 isolation guidance; does not change guidance for Vanderbilt Health employees, patients or facilities

NIH-funded trial to determine if immunomodulation can improve brain and cardiovascular dysfunction in Long COVID

Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first Phase III, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID.

1 2 3 40